DrugPatentWatch Database Preview
HORIZANT Drug Profile
Which patents cover Horizant, and when can generic versions of Horizant launch?
Horizant is a drug marketed by Arbor Pharms Llc and is included in one NDA. There are six patents protecting this drug.
This drug has one hundred and forty-seven patent family members in twenty-five countries.
The generic ingredient in HORIZANT is gabapentin enacarbil. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gabapentin enacarbil profile page.
Summary for HORIZANT
| International Patents: | 147 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 36 |
| Clinical Trials: | 10 |
| Patent Applications: | 75 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for HORIZANT |
| DailyMed Link: | HORIZANT at DailyMed |
Generic Entry Opportunity Date for HORIZANT
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for HORIZANT
| Drug Class | Anti-epileptic Agent |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Synonyms for HORIZANT
| (1-(((((1RS)-1-((2-methylpropanoyl)oxy)ethoxy)carbonyl)amino)methyl)cyclohexyl)acetic acid |
| {[(1-Isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-Cyclohexane Acetic Acid |
| {[(alpha-Isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-Cyclohexane Acetic Acid |
| {1-[({[1-(isobutyryloxy)ethoxy]carbonyl}amino)methyl]cyclohexyl}acetic acid |
| 1-[[[[1-(2-Methyl-1-oxopropoxy)ethoxy]carbonyl]amino]methyl]cyclohexaneacetic acid |
| 1-{[(alpha-Isobutanovloxyethoxy)carbonyl]aminomethyl}-1-Cyclohexane Acetic Acid |
| 1-{[(alpha-Isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-Cyclohexane Acetic Acid |
| 1-{[(alpha-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexaneacetic acid |
| 2-(1-((((1-(Isobutyryloxy)ethoxy)carbonyl)amino)methyl)cyclohexyl)acetic acid |
| 2-(1-(((1-(isobutyryloxy)ethoxy)carbonyl)methyl)cyclohexyl)acetic acid |
| 2-(1-(((1-(isobutyryloxy)ethoxy)carbonylamino)methyl)cyclohexyl)acetic acid |
| 2-[1-[[[1-[(2-Methylpropanoyl)oxy]ethoxy]carbonylamino]methyl]cyclohexyl]acetic acid |
| 2-[1-[[1-(2-methylpropanoyloxy)ethoxycarbonylamino]methyl]cyclohexyl]acetic acid |
| 296G729 |
| 3687AH |
| 478296-72-9 |
| 791632-57-0 |
| A20372 |
| AC-27644 |
| ACN-028536 |
| AK170416 |
| AKOS025290727 |
| AN-16701 |
| API0008802 |
| ASP-8825 |
| ASP8825 |
| CHEBI:68840 |
| CHEMBL1628502 |
| CS-1698 |
| Cyclohexaneacetic acid, 1-((((1-(2-methyl-1-oxopropoxy)ethoxy)carbonyl)amino)methyl)- |
| Cyclohexaneacetic acid,1-[[[[1-(2-methyl-1-oxopropoxy)ethoxy]carbonyl]amino]methyl]- |
| D05KBU |
| D09539 |
| DB08872 |
| FT-0753836 |
| Gabapentin enacarbil |
| Gabapentin enacarbil (JAN/USAN/INN) |
| Gabapentin enacarbil [USAN:INN] |
| Gabapentin-XP |
| gabapentina enacarbilo |
| gabapentine enacarbil |
| Gabapentinenacarbil |
| gabapentinum enacarbilum |
| GSK 1838262 |
| GSK-1838262 |
| GSK1838262 |
| GTPL7560 |
| Horizant (TN) |
| Horizant, Regnite |
| Horizant|||Regnite|||XP 13512 |
| HY-16216 |
| MFCD09954124 |
| OR068058 |
| OR272863 |
| PB32822 |
| Q-1947 |
| Regnite |
| SCHEMBL25455 |
| Solzira |
| TZDUHAJSIBHXDL-UHFFFAOYSA-N |
| XP 13512 |
| XP-053 |
| XP-13512 |
| XP13512 |
US Patents and Regulatory Information for HORIZANT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arbor Pharms Llc | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-002 | Dec 13, 2011 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Arbor Pharms Llc | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-001 | Apr 6, 2011 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Arbor Pharms Llc | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-002 | Dec 13, 2011 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Arbor Pharms Llc | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-001 | Apr 6, 2011 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Arbor Pharms Llc | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-002 | Dec 13, 2011 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Arbor Pharms Llc | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-001 | Apr 6, 2011 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for HORIZANT
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 101068538 | ➤ Sign Up |
| Singapore | 147437 | ➤ Sign Up |
| Australia | 2007203364 | ➤ Sign Up |
| Canada | 2541752 | ➤ Sign Up |
| Australia | 2003297676 | ➤ Sign Up |
| Hong Kong | 1087628 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
